Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity

Chankyu Lee, Seuk Keun Choi, Rock Ki Kim, Heeyoun Kim, Yoon Hee Whang, H. Pharm, Hyunwoo Cheon, Do Young Yoon, Chan Wha Kim, Yeong Ok Baik, Sung Soo Park, Inhwan Lee

Research output: Contribution to journalArticle

Abstract

A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13®. Among the shared serotypes in both PCV15 and Prevnar13®, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13®. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.

Original languageEnglish
JournalBiologicals
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Conjugate Vaccines
Pneumococcal Vaccines
Vaccines
Antibodies
Antigens
Polysaccharides
Phosphates
Rabbits
Proteins
Aluminum
Serogroup
Enzyme-Linked Immunosorbent Assay

Keywords

  • Enzyme-linked immunosorbent assay
  • Immunogenicity
  • Opsonophagocytic activity
  • Polyvalent pneumococcal conjugate vaccine

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity. / Lee, Chankyu; Choi, Seuk Keun; Kim, Rock Ki; Kim, Heeyoun; Whang, Yoon Hee; Pharm, H.; Cheon, Hyunwoo; Yoon, Do Young; Kim, Chan Wha; Baik, Yeong Ok; Park, Sung Soo; Lee, Inhwan.

In: Biologicals, 01.01.2019.

Research output: Contribution to journalArticle

Lee, Chankyu ; Choi, Seuk Keun ; Kim, Rock Ki ; Kim, Heeyoun ; Whang, Yoon Hee ; Pharm, H. ; Cheon, Hyunwoo ; Yoon, Do Young ; Kim, Chan Wha ; Baik, Yeong Ok ; Park, Sung Soo ; Lee, Inhwan. / Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity. In: Biologicals. 2019.
@article{22b55b7cedb8462795fb801f8330619c,
title = "Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity",
abstract = "A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13{\circledR}. Among the shared serotypes in both PCV15 and Prevnar13{\circledR}, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13{\circledR}. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.",
keywords = "Enzyme-linked immunosorbent assay, Immunogenicity, Opsonophagocytic activity, Polyvalent pneumococcal conjugate vaccine",
author = "Chankyu Lee and Choi, {Seuk Keun} and Kim, {Rock Ki} and Heeyoun Kim and Whang, {Yoon Hee} and H. Pharm and Hyunwoo Cheon and Yoon, {Do Young} and Kim, {Chan Wha} and Baik, {Yeong Ok} and Park, {Sung Soo} and Inhwan Lee",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.biologicals.2019.07.005",
language = "English",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity

AU - Lee, Chankyu

AU - Choi, Seuk Keun

AU - Kim, Rock Ki

AU - Kim, Heeyoun

AU - Whang, Yoon Hee

AU - Pharm, H.

AU - Cheon, Hyunwoo

AU - Yoon, Do Young

AU - Kim, Chan Wha

AU - Baik, Yeong Ok

AU - Park, Sung Soo

AU - Lee, Inhwan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13®. Among the shared serotypes in both PCV15 and Prevnar13®, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13®. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.

AB - A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13®. Among the shared serotypes in both PCV15 and Prevnar13®, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13®. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.

KW - Enzyme-linked immunosorbent assay

KW - Immunogenicity

KW - Opsonophagocytic activity

KW - Polyvalent pneumococcal conjugate vaccine

UR - http://www.scopus.com/inward/record.url?scp=85070502469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070502469&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2019.07.005

DO - 10.1016/j.biologicals.2019.07.005

M3 - Article

JO - Biologicals

JF - Biologicals

SN - 1045-1056

ER -